Chronic inflammation drives many obesity-associated conditions including atherosclerosis.
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Chronic inflammation drives many obesity-associated conditions including atherosclerosis.
GlycA, a marker of systemic inflammation with lower intra-individual variability than high sensitivity C-reactive protein, is independently associated with incident cardiovascular events and mortality. Although GlycA is elevated in obesity, correlations with anthropometric measures are modest and the effect of body weight loss on GlycA is untested. Obese (body mass index [BMI] 44.6 AE 6.6 kg/m 2 ), non-diabetic women (33.7 AE 8.2 years) undergoing Roux-en-Y gastric bypass (n = 23) or sleeve gastrectomy (n = 31) were prospectively studied at baseline, 6 and 12 months postprocedure. Women with normal BMI (n = 14) served as controls. Bariatric surgery significantly reduced GlycA by 6 months (451 AE 47 μmol/L vs. 383 AE 50 μmol/L; P < 0.001) with further reduction at 12 months (348 AE 41 μmol/L; P < 0.001) and no difference between procedures. At 12 months, despite 41% of surgical subjects maintaining BMI >30 kg/m 2 , GlycA levels did not differ between surgical and control subjects (P = 0.13). Increased high density lipoprotein particle size was strongly associated with reduced GlycA (r = −0.49; P < 0.001) and was found to mediate up to 43% of its body weight-loss-associated fall. This is the first study to demonstrate that surgical body weight loss markedly reduces levels of GlycA.
bariatric surgery, cardiovascular disease, GlycA, inflammation, obesity, risk GlycA is a novel, composite nuclear magnetic resonance (NMR)-measured biomarker that integrates quantities of several abundant acute phase glycoproteins to provide a more global assessment of inflammation with much lower intra-individual variability than hsCRP. 5 GlycA has been shown to be a strong and independent predictor of CVD, even among patients with concurrent inflammatory diseases. [6] [7] [8] Furthermore, recent data suggest incorporation of GlycA improves the discriminatory capacity of traditional CVD risk models, independent of hsCRP. 5, 6 High density lipoprotein (HDL), a traditional measure of CVD risk, is believed to be cardioprotective through several mechanisms including anti-inflammatory activity. 9 However, impaired HDL function frequently characterizes obesity, 10 possibly contributing to excess inflammation and CVD risk. Notably, both HDL and GlycA (in opposite directions) have been associated with active vascular inflammation. 
| METHODS
Non-smoking, non-diabetic, premenopausal Hispanic women, age 
| RESULTS
The 77 subjects enrolled in this study were young (32.4 AE 7.7 years) and severely obese (44.1 AE 6.4 kg/m 2 ). They did not differ from the 54 subjects who underwent surgery and completed all the study procedures, and whose data are presented in Table 1 . Although, by design, subjects did not exhibit insulin resistance or dyslipidaemia necessitating medications, 28/54 subjects met International Diabetes
Federation metabolic syndrome diagnostic criteria 16 preoperatively.
Obese subjects also exhibited very elevated levels of inflammatory markers (Table 1) . Preoperatively, 44/54 subjects had elevated GlycA (≥410 μmol/L) and 47/54 subjects had hsCRP >3 mg/L. No normal BMI subject exhibited elevated inflammatory markers.
Subjects lost significant weight at 6 (−27.4% AE 5.0%) and 12 months (−33.3% AE 7.4%). GlycA levels significantly decreased at 6 months and were further reduced at 12 months after surgery In preoperative obese subjects, GlycA significantly correlated with hsCRP (r = 0.68; P < 0.001; Figure S1 ), but not body weight (r = 0.24; P = 0.08), BMI (r = 0.14; P = 0.33), waist circumference (r = 0.18; P = 0.20) or waist : hip ratio (r = 0.17; P = 0.22). One year postoperatively, GlycA was no longer associated with hsCRP (r = 0.24; P = 0.09). Postoperative changes in GlycA were strongly positively associated with changes in body weight (r = 0.41; P = 0.002; Figure 1C ), hsCRP (r = 0.36; P = 0.008) and HbA1c (r = 0.31; P = 0.03; Figure 1D ), and inversely with changes in mean HDL particle size (r = −0.49; P < 0.001; Figure 1E ) and adiponectin (r = −0.47; (A) GlycA (mean AE standard deviation) and (B) hsCRP (median AE interquartile range) in normal BMI women and obese women before and at 6 and 12 months following bariatric surgery. Comparisons with baseline inflammatory marker values were performed using RMANOVA and post-hoc paired sample t-tests (GlycA) or the Friedman test and post-hoc Wilcoxon signed rank tests (hsCRP). Comparisons of obese subjects with normal BMI control subjects were performed using independent two-sample t-tests (GlycA) or Mann-Whitney U tests (hsCRP). Pairwise Pearson correlations between changes in GlycA from before to 12 months following bariatric surgery with (C) body weight, (D) HbA1c and (E) HDL size. * P < 0.001 vs. baseline (Table S1 ).
| DISCUSSION
This is the first study of the effect of body weight loss or bariatric surgery on the novel composite inflammatory marker, GlycA. In this study of 54 Hispanic women followed for over 1 year, we showed that obesity, even in predominantly metabolically healthy individuals, is characterized by markedly elevated GlycA. We demonstrated that bariatric surgery is largely effective in normalizing GlycA levels, even in patients who remain obese, and that body weight-loss-associated reduction in
GlycA may be partly mediated by HDL particle size increases.
The pathophysiologic link between systemic inflammation and atherosclerosis is well established and interventions aimed specifically at reducing inflammation can reduce adverse CVD outcomes. 18 The precise nature of the association between obesity, inflammation and CVD is less clearly understood. Many inflammatory markers associated with CVD 3, 18 are also elevated in obesity, including interleukin-6, TNFα, interleukin-1β and hsCRP. 1 Of these, hsCRP is the most widely studied and clinically validated marker of systemic inflammation in CVD and obesity. 1 However, chronic inflammation is heterogeneous in nature and, as a single marker of inflammation with sizable intraindividual variability, hsCRP may incompletely represent an individual's inflammatory status. 2 The relevance of this to CVD risk, specifically in obesity, is highlighted by the analysis of MESA described above. 4 GlycA has been associated with CVD and all-cause mortality, even after adjusting for hsCRP, suggesting that GlycA captures different aspects of inflammation to hsCRP. P-values derived are from comparisons using independent two-sample t-tests for normally distributed variables and Mann-Whitney U tests for hsCRP, triglycerides and adiponectin. Blood pressure is represented as systolic blood pressure/diastolic blood pressure.
cohorts, 5, 19 and levels ≥417 μmol/L were associated with 29% greater odds of incident CVD in the Women's Health Study. 8 Although they require validation in larger diverse cohorts, our data suggest that GlycA may be useful for further risk stratification in patients with a history of obesity who have lost substantial body weight.
Finally, we found that reductions in GlycA following bariatric surgery were strongly related to reductions in body weight and HbA1c, as well as increased HDL particle size. In further modelling, changes in HDL particle size appeared to explain much of the association with reduced body weight. Anti-inflammatory activity is one mechanism by which HDL is felt to be atheroprotective 9 and HDL size has been inversely associated with vascular inflammation on PET, 11 a measure of atherosclerotic CVD that also strongly correlates with GlycA. 6 Although some recent work suggests small, rather than large, HDL particles may be most associated with reduced CVD risk, 5,13 these researchers also found that the associations of HDL with outcomes are altered in the setting of elevated GlycA. 5 While the current study does not allow determination of causation, the sizable mediation effect by HDL particle size presents a potential plausible mechanism to evaluate in future studies.
This study has a number of limitations. In order to reduce confounding in our limited sample, our cohort was quite homogenous.
Thus, it is not known if our findings can be extrapolated to men, older individuals, other ethnicities, or how common medications may influence GlycA in obesity. Furthermore, findings from our 12-month time point may not reflect changes that occur with additional body weight loss or alternative body weight loss techniques.
In conclusion, our study is the first to demonstrate the ability of bariatric surgery to reduce inflammation as indicated by elevated GlycA. Our data also suggest that GlycA may be an attractive inflammatory marker to discriminate CVD risk in metabolically healthy obesity. Additional studies are needed to further evaluate mechanisms underlying GlycA reduction with body weight loss in obesity, and if reduction of GlycA in this patient population correlates with clinically relevant endpoints.
